Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Screening for cervical cancer in resource-limited settings

Lynette Denny, MD, PhD
Section Editor
Barbara Goff, MD
Deputy Editor
Sandy J Falk, MD, FACOG


Cervical cancer is the most common malignancy among women in the developing world, and more than 85 percent of worldwide cervical cancer deaths occur in these settings [1,2]. Effective strategies for cervical cancer screening and treatment of cervical intraepithelial neoplasia, a precursor to cancer, have been in place for more than 70 years and, where applied, have dramatically reduced the incidence of and mortality from this disease [3,4].

However, standard strategies such as cervical cytology, human papillomavirus testing, and colposcopy are often not possible in developing settings due to economic and other infrastructure issues. Health care resources and disease burden vary between and within countries, making it difficult to draw general conclusions regarding screening strategies for the entire developing world. Addressing individual countries is beyond the scope of this topic review. Therefore, cervical cancer screening in health care systems in which cytology or colposcopy are not feasible will be reviewed here.

The general approach to and tests used for cervical cancer screening are discussed separately. (See "Screening for cervical cancer" and "Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing" and "Cervical cancer screening tests: Visual inspection methods".)


Cervical cancer comprises 12 percent of all cancers among women worldwide and is the fourth most common cancer after breast, lung, and colon cancer [1]. Over 85 percent of new cases are diagnosed in the developing world, and in these countries, it is the most common cancer in women [5]. The following links provide global rates of cervical cancer in 2012 from the World Health Organization's GLOBOCAN database: incidence and mortality.


Barriers to implementing programs for cervical cancer prevention include competing health care demands and economic, social, and political issues [6].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Apr 18, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.
  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 V1.0 Cancer incidence and Mortality Worldwide: IARC CancerBase no. 11. Lyon, France. International Agency for Research on Cancer; 2013. Available at http://globocan.iarc.fr.
  3. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318:904.
  4. Willoughby BJ, Faulkner K, Stamp EC, Whitaker CJ. A descriptive study of the decline in cervical screening coverage rates in the North East and Yorkshire and the Humber regions of the UK from 1995 to 2005. J Public Health (Oxf) 2006; 28:355.
  5. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr.
  6. Denny L. Control of cancer of the cervix in low- and middle-income countries. Ann Surg Oncol 2015; 22:728.
  7. http://www.infoplease.com/ipa/A0933893.html (Accessed on April 21, 2011).
  8. The burden of disease and mortality by condition: Data, Methoda and Results for the year 2001 http://www.ncbi.nlm.nih.gov/books/NBK11808/ (Accessed on April 21, 2011).
  9. http://www.infoplease.com/science/health/expenditures-country-2006.html (Accessed on April 21, 2011).
  10. Cancer Incidence in Five Continents - Volume VIII. In: IARC Scientific Publications no. 155, DM Parkin, SL Whelan, J Ferlay, L Teppo, DB Thomas (Eds), International Agencey for Research on Cancer, Lyon, France 2002.
  11. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008; 5:e132.
  12. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370:398.
  13. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005; 353:2158.
  14. Screening for cervical cancer. In: Common screening tests, Eddy DM (Ed), American College of Physicians, Philadelphia 1991. p.255.
  15. Pretorius RG, Bao YP, Belinson JL, et al. Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer 2007; 121:2218.
  16. Schiller W. Leucoplakia, leucokeratosis, and carcinoma of the cervix. Am J Obstet Gynecol 1938; 35:17.
  17. Sankaranarayanan R, Shyamalakumary B, Wesley R, et al. Visual inspection with acetic acid in the early detection of cervical cancer and precursors. Int J Cancer 1999; 80:161.
  18. Shastri SS, Mittra I, Mishra G, et al. Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India (abstract). J Clin Oncol 2013; 31:2.
  19. Cecchini S, Bonardi R, Mazzotta A, et al. Testing cervicography and cervicoscopy as screening tests for cervical cancer. Tumori 1993; 79:22.
  20. Ottaviano M, La Torre P. Examination of the cervix with the naked eye using acetic acid test. Am J Obstet Gynecol 1982; 143:139.
  21. Megevand E, Denny L, Dehaeck K, et al. Acetic acid visualization of the cervix: an alternative to cytologic screening. Obstet Gynecol 1996; 88:383.
  22. Sankaranarayanan R, Wesley R, Somanathan T, et al. Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. Cancer 1998; 83:2150.
  23. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet 1999; 353:869.
  24. Denny L, Kuhn L, Pollack A, et al. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000; 89:826.
  25. Belinson JL, Pretorius RG, Zhang WH, et al. Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol 2001; 98:441.
  26. Denny L, Kuhn L, Pollack A, Wright TC Jr. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 2002; 94:1699.
  27. Cronjé HS, Parham GP, Cooreman BF, et al. A comparison of four screening methods for cervical neoplasia in a developing country. Am J Obstet Gynecol 2003; 188:395.
  28. Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123:153.
  29. Prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy. World Health Organization; International Agency for Research on Cancer, Geneva, 2012.
  30. Sankaranarayanan R, Shastri SS, Basu P, et al. The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia. Cancer Detect Prev 2004; 28:345.
  31. Sangwa-Lugoma G, Mahmud S, Nasr SH, et al. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer 2006; 119:1389.
  32. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360:1385.
  33. Crum C, Harvard University, 2009, personal communication.
  34. http://www1.qiagen.com/about/pressreleases/PressReleaseView.aspx?PressReleaseID=217 (Accessed on April 21, 2011).
  35. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9:929.
  36. Kuhn L, Denny L, Pollack A, et al. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000; 92:818.
  37. Gök M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010; 340:c1040.
  38. Petignat P, Faltin DL, Bruchim I, et al. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007; 105:530.
  39. Ogilvie GS, Patrick DM, Schulzer M, et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 2005; 81:207.
  40. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011; 378:1868.
  41. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285:3107.
  42. Denny L, Kuhn L, Risi L, et al. Two-stage cervical cancer screening: an alternative for resource-poor settings. Am J Obstet Gynecol 2000; 183:383.
  43. Santesso N, Schünemann H, Blumenthal P, et al. World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2012; 118:97.
  44. Denny L, Kuhn L, De Souza M, et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005; 294:2173.
  45. Denny L, Kuhn L, Hu CC, et al. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010; 102:1557.
  46. Gaffikin L, Blumenthal PD, Emerson M, et al. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet 2003; 361:814.
  47. Sankaranarayanan R, Rajkumar R, Esmy PO, et al. Effectiveness, safety and acceptability of 'see and treat' with cryotherapy by nurses in a cervical screening study in India. Br J Cancer 2007; 96:738.
  48. http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/index.html (Accessed on December 13, 2013).
  49. Ebisch RM, Rovers MM, Bosgraaf RP, et al. Evidence supporting see-and-treat management of cervical intraepithelial neoplasia: a systematic review and meta-analysis. BJOG 2016; 123:59.